These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 10805055

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lysophosphatidylcholine molecular species in low density lipoprotein of type 2 diabetes.
    Shi AH, Yoshinari M, Wakisaka M, Iwase M, Fujishima M.
    Horm Metab Res; 1999 Apr; 31(4):283-6. PubMed ID: 10333086
    [Abstract] [Full Text] [Related]

  • 4. Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients.
    Harada N, Kashiwagi A, Nishio Y, Kikkawa R.
    Diabetes Res Clin Pract; 1999 Feb; 43(2):111-20. PubMed ID: 10221663
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
    Yamashita S, Arai H, Bujo H, Masuda D, Ohama T, Ishibashi T, Yanagi K, Doi Y, Nakagawa S, Yamashiro K, Tanabe K, Kita T, Matsuzaki M, Saito Y, Fukushima M, Matsuzawa Y, PROSPECTIVE Study Group.
    J Atheroscler Thromb; 2021 Feb 01; 28(2):103-123. PubMed ID: 32336695
    [Abstract] [Full Text] [Related]

  • 8. Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
    Yasuda G, Ando D, Hirawa N, Umemura S.
    Ren Fail; 2010 Jul 01; 32(6):680-6. PubMed ID: 20540635
    [Abstract] [Full Text] [Related]

  • 9. Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits.
    Lauridsen ST, Mortensen A.
    Atherosclerosis; 1999 Jan 01; 142(1):169-78. PubMed ID: 9920518
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.
    Saku K, Zhang B, Hirata K, Okura Y, Bai H, Liu R, Arakawa K.
    Eur J Clin Pharmacol; 1993 Jan 01; 44(6):535-9. PubMed ID: 8405008
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Probucol normalizes cholesteryl ester transfer in IDDM.
    Bagdade JD, Stein E, Ritter MC.
    Diabetes Care; 1995 Oct 01; 18(10):1341-6. PubMed ID: 8721935
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New Horizons for Probucol, an Old, Mysterious Drug.
    Yamashita S, Masuda D, Matsuzawa Y.
    J Atheroscler Thromb; 2021 Feb 01; 28(2):100-102. PubMed ID: 32507832
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
    Anikin VV, Savin VV, Lupanov VP, Razygraev RA.
    Ter Arkh; 2000 Feb 01; 72(8):28-30. PubMed ID: 11019422
    [Abstract] [Full Text] [Related]

  • 19. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
    Reaven PD, Parthasarathy S, Beltz WF, Witztum JL.
    Arterioscler Thromb; 1992 Mar 01; 12(3):318-24. PubMed ID: 1547191
    [Abstract] [Full Text] [Related]

  • 20. Effects of probucol on lipoprotein protein kinetics.
    Nestel PJ.
    Artery; 1982 Mar 01; 10(2):95-8. PubMed ID: 7092582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.